The in vitro activity of
tigecycline was evaluated against 819 baseline pathogens isolated from 383 patients enrolled in the phase 3 clinical trial investigating the efficacy of
tigecycline in
hospital acquired pneumonia (HAP). The trials were global, enrolling patients in 27 countries.
Tigecycline was active against the most prevalent pathogens in HAP, including gram-positive and gram-negative strains (90% of MICs ≤2 µg/mL for the entire collection). The spectrum of activity of
tigecycline included important pathogens such as Staphylococcus aureus (including methicillin-resistant S. aureus), Enterococcus faecalis, Streptococcus pneumoniae, Acinetobacter baumannii/calcoaceticus complex, Escherichia coli, Klebsiella
pneumonia, and Enterobacter cloacae. As reported previously, a few genera, such as Pseudomonas aeruginosa and the Proteeae, were generally less susceptible to
tigecycline by comparison to other gram-negative pathogens. The excellent in vitro, expanded, broad-spectrum activity of
tigecycline in the clinical isolates confirmed the potential utility of
tigecycline for pathogens associated with with
hospital acquired pneumonia infections.